Alex has experience of patent litigation on behalf of major global R&D based pharmaceutical companies and has worked on high profile patent and SPC cases in the High Court, Court of Appeal and Court of Justice of the European Union (CJEU). He has also attended and advised on strategy in relation to opposition hearings at the European Patent Office.
Alex uses his strong scientific credentials to work closely with clients to develop case theories and to develop and implement multi-jurisdictional patent litigation strategies. He has a track record of working collaboratively in teams of leading patent litigators from numerous firms across the globe, and has particular experience of coordinating pan-European patent litigation.
Alex has worked on both originator v. originator patent disputes, as well as originator v. generic disputes, and has acted for clients such as AbbVie, Eisai, Gilead, Roche, Sanofi and Takeda.
Alex's experience includes advising:
- Roche in their defence against Pfizer Limited's claim in the UK High Court for so-called 'Arrow declarations' relating to pending European Patent applications owned by Roche covering the use of Roche/Genentech's blockbuster anticancer drug Avastin® (bevacizumab), a monoclonal antibody
- Gilead in UK litigation and proceedings before the CJEU regarding its leading blockbuster HIV therapy, Truvada® (tenofovir disoproxil and emtricitabine)
- Gilead in multi-jurisdictional patent litigation, including UK actions in the High Court and Court of Appeal concerning Gilead's ground-breaking drug Sovaldi® (sofosbuvir) for the treatment of HCV
- Sanofi in the pan-European defence and enforcement of the SPCs protecting irbesartan
- Eisai in coordinating the pan-European patent litigation across Europe concerning Eisai's blocbuster drugs Aricept®, an Alzheimer's treatment, and Pariet®, an anti-ulcer drug
- Roche in preliminary injunction proceedings regarding generic versions of its osteoporosis treatment, Bonviva® (ibandronate)
- A research funding organisation in alternative dispute resolution (mediation) with a pharmaceutical company regarding disputed royalties payable under a patent licence
Prior to his career in law, Alex was a post-doctoral research associate of Imperial College London funded by the Medical Research Council, specialising in molecular biology.
Alex has a PhD in molecular biology from the University of Cambridge, and a first class BSc (Hons) degree in Biochemistry and Molecular Biology from the University of Manchester Institute of Science and Technology (UMIST). Alex holds a Postgraduate Diploma in Intellectual Property Law and Practice from the University of Oxford.
Alex is a solicitor advocate with rights of audience in all civil proceedings in the UK and is admitted as a solicitor in England & Wales and in Ireland.